Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway

Abstract

Abstract. Long non-coding RNAs (lncRNAs) serve an important role in numerous human diseases, including cancer. Abnormal expression of lncRNAs has been associated with a number of tumor types; however, the underlying mechanisms through which lncRNA functions have yet to be elucidated. The present study primarily focuses on insulin-like growth factor 2 antisense 1 (Igf2as), a lncRNA reported to be differentially expressed in hepatocellular carcinoma (HCC). Reverse transcription-quantitative polymerase chain reaction analysis was used to determine the level of Igf2as in HCC cells and tissues. Flow cytometry was used to determine the level of cell apoptosis following Igf2as suppression and western blot analysis was used to identify altered protein expression levels. The results demonstrated that Igf2as was upregulated in HCC cells and tissues, and that the inhibition of Igf2as using a targeted small interfering RNA (si-Igf2as), significantly decreased cell proliferation and increased apoptosis. Western blot analysis identified that the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway was inhibited in cells transfected with si-Igf2as. In addition, cell migration was markedly reduced by the knockdown of Igf2as. These results suggest that lncRNA Igf2as may control hepatocellular progression primarily through the regulation of the ERK/ MAPK signaling pathway.

LncRNA NR2F1‐AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR‐363

“…For example, lncRNA UBE2CP3 was frequently up‐regulated in HCC samples and promotes hepatocellular carcinoma tumour metastasis via regulating epithelial‐mesenchymal transition and inducing cell invasion and migration . LncRNA Igf2as was upregulated in HCC cells and tissues and controlled hepatocellular carcinoma progression through the ERK/MAPK signalling pathway …”

“…8 LncRNA Igf2as was upregulated in HCC cells and tissues and controlled hepatocellular carcinoma progression through the ERK/MAPK signalling pathway. 9 Oxaliplatin resistance is one of the most vital barriers for HCC chemotherapy. LncRNAs have been proved to modulate the chemotherapy resistance of HCC on molecular level.…”

LncRNA CASC15 promotes colon cancer cell proliferation and metastasis by regulating the miR‑4310/LGR5/Wnt/β‑catenin signaling pathway

“…Abnormal expression of lncRNAs is often observed in cancers, including CC (15). For instance, lncRNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway (16). LncRNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15 (17).…”

Long noncoding RNA IGF2AS regulates high‐glucose induced apoptosis in human retinal pigment epithelial cells

“…In hepatitis C, IGF2‐AS was shown to regulate virus replication through the interaction of signal transducer and activator of transcription 3 (STAT3) . In various human cancers, IGF2‐AS was demonstrated to be dysregulated and have functional or prognostic implications in oral squamous cell carcinoma, hepatocellular cancer, or lung cancer . Specifically, in local anesthesia‐induced neurotoxicity, inhibition of IGF2‐AS was demonstrated to coactive neurotrophins, such as brain derived neurotrophin (BDNF) and neurotrophin‐3 (NT3) to reduce cellular apoptosis in dorsal root ganglion neurons .…”